How Neuropeptide Y Influences Asthma, COPD, and Other Lung Diseases Through the Immune System
Neuropeptide Y (NPY), a 36-amino-acid peptide neurotransmitter, plays critical and disease-specific roles in asthma, COPD, and pulmonary fibrosis through its Y1 receptor and airway immune modulation.
Quick Facts
What This Study Found
Neuropeptide Y, a 36-amino-acid polypeptide neurotransmitter, acts through a family of G-protein-coupled receptors with six subtypes (Y1-Y6), of which Y1, Y2, Y4, and Y5 are functional in humans. The Y1 receptor plays particularly important roles in immune responses across multiple organs including the respiratory system.
NPY and the Y1 receptor have critical roles in the pathogenesis of asthma, COPD, and idiopathic pulmonary fibrosis. Notably, the effects of NPY on airway immune responses and disease pathogenesis differ among these respiratory conditions, indicating that NPY's influence is disease-specific rather than following a single unified mechanism.
Key Numbers
How They Did This
This is a narrative review article that synthesizes published research on NPY's involvement in airway immune responses and respiratory disease pathogenesis. The authors examined literature covering NPY receptor biology, airway immunology, and the peptide's roles across multiple respiratory conditions.
Why This Research Matters
Chronic respiratory diseases like asthma and COPD affect hundreds of millions of people worldwide, and current treatments don't work for everyone. By mapping out how a single neuropeptide influences lung immunity differently across diseases, this review highlights NPY receptors as potential therapeutic targets. Drugs that modulate NPY signaling could offer new treatment strategies tailored to specific respiratory conditions.
The Bigger Picture
This review sits at the intersection of neuropeptide biology and pulmonary immunology — two fields that have traditionally been studied separately. The growing recognition that neuropeptides like NPY directly modulate immune responses challenges the old separation between the nervous and immune systems. Understanding these neuro-immune connections in the lungs could reshape how we approach respiratory disease treatment.
What This Study Doesn't Tell Us
As a narrative review, this study does not present original experimental data and may be subject to selection bias in the literature covered. The abstract does not detail the specific mechanisms by which NPY affects each disease, and much of the underlying research may come from animal models that don't perfectly translate to human disease.
Questions This Raises
- ?Could selective Y1 receptor modulators be developed as targeted therapies for specific respiratory diseases?
- ?Why does NPY have different effects across asthma, COPD, and pulmonary fibrosis — what molecular mechanisms drive these disease-specific differences?
- ?How do NPY levels change during acute exacerbations versus stable phases of chronic respiratory diseases?
Trust & Context
- Key Stat:
- 36-Amino-Acid Peptide, 3 Major Lung Diseases NPY influences asthma, COPD, and pulmonary fibrosis through different immune mechanisms, primarily via the Y1 receptor
- Evidence Grade:
- This is a narrative review article that synthesizes existing research without generating new data or using systematic review methodology. While it provides a valuable overview of NPY's roles in respiratory disease, it ranks below systematic reviews and original clinical studies in evidence strength.
- Study Age:
- Published in 2024, this review captures the current understanding of NPY's roles in respiratory immunology, incorporating recent advances in neuropeptide receptor biology.
- Original Title:
- The Roles of Neuropeptide Y in Respiratory Disease Pathogenesis via the Airway Immune Response.
- Published In:
- Acta medica Okayama, 78(2), 95-106 (2024)
- Database ID:
- RPEP-08441
Evidence Hierarchy
Frequently Asked Questions
What is neuropeptide Y and what does it do in the body?
Neuropeptide Y (NPY) is a 36-amino-acid peptide that acts as a neurotransmitter — a chemical messenger in the nervous system. It helps regulate many body functions including appetite, stress response, and immune activity. In the lungs, NPY influences how the immune system responds to environmental irritants and infections through its receptors, particularly the Y1 receptor.
Could neuropeptide Y become a target for treating asthma or COPD?
This review suggests it's a possibility. NPY and its Y1 receptor play critical roles in how asthma, COPD, and pulmonary fibrosis develop. However, because NPY affects each disease differently, treatments would need to be specifically designed for each condition. Research is still in early stages, and no NPY-targeting respiratory drugs are currently available.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08441APA
Itano, Junko; Kiura, Katsuyuki; Maeda, Yoshinobu; Miyahara, Nobuaki. (2024). The Roles of Neuropeptide Y in Respiratory Disease Pathogenesis via the Airway Immune Response.. Acta medica Okayama, 78(2), 95-106. https://doi.org/10.18926/AMO/66912
MLA
Itano, Junko, et al. "The Roles of Neuropeptide Y in Respiratory Disease Pathogenesis via the Airway Immune Response.." Acta medica Okayama, 2024. https://doi.org/10.18926/AMO/66912
RethinkPeptides
RethinkPeptides Research Database. "The Roles of Neuropeptide Y in Respiratory Disease Pathogene..." RPEP-08441. Retrieved from https://rethinkpeptides.com/research/itano-2024-the-roles-of-neuropeptide
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.